Pharma Mar S.A.
Biopharmaceutical company developing oncology treatments from marine sources.
PHM | MC
Overview
Corporate Details
- ISIN(s):
- ES0169501022 (+1 more)
- LEI:
- 959800QWKZ45ZQC2AV58
- Country:
- Spain
- Address:
- Avenida de los Reyes 1 Polígono Industrial La Mina, 28770 Colmenar Viejo
- Website:
- https://pharmamar.com/en/
- Sector:
- Manufacturing
Description
Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-28 00:00 |
Corporate Governance Report - Pharma Mar S.A.
|
Spanish | 226.3 KB | ||
| 2023-02-28 00:00 | Spanish | 2.0 MB | |||
| 2023-02-28 00:00 | Spanish | 7.4 MB | |||
| 2023-02-28 00:00 | Spanish | 10.2 MB | |||
| 2023-02-16 08:25 |
La Sociedad anuncia el cierre del estudio de fase III Neptuno con plitidepsina …
|
Spanish | 116.7 KB | ||
| 2023-01-31 08:27 |
La Sociedad anuncia la aprobación de Zepzelca® (lurbinectedina) para el tratami…
|
Spanish | 104.4 KB | ||
| 2023-01-24 08:28 |
La Sociedad anuncia la aprobación de Zepzelca® (lurbinectedina) para el tratami…
|
Spanish | 130.8 KB | ||
| 2023-01-09 11:16 |
La Sociedad remite detalle de las operaciones del Contrato de Liquidez comprend…
|
English | 111.5 KB | ||
| 2022-12-30 08:27 |
Nota de prensa informando sobre la entrada en fase clínica de un nuevo compuest…
|
Spanish | 94.9 KB | ||
| 2022-12-21 17:35 |
La Sociedad comunica el nombramiento por cooptación de nuevo Consejero, modific…
|
Spanish | 42.1 KB | ||
| 2022-12-12 08:26 |
La Sociedad anuncia que ha recibido por parte de Janssen un pago de 10 millones…
|
Spanish | 110.7 KB | ||
| 2022-10-27 17:37 |
La Sociedad publica información financiera correspondiente al tercer trimestre …
|
Spanish | 1.2 MB | ||
| 2022-10-06 17:42 |
La Sociedad remite detalle de las operaciones del Contrato de Liquidez comprend…
|
English | 117.6 KB | ||
| 2022-10-03 11:19 |
La Sociedad lamenta comunicar el fallecimiento de su Consejero D. José Félix Pé…
|
Spanish | 35.0 KB | ||
| 2022-09-27 17:42 |
La Sociedad anuncia el cese de la actividad de diagnóstico que desarrolla a tra…
|
Spanish | 33.8 KB |
Automate Your Workflow. Get a real-time feed of all Pharma Mar S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharma Mar S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharma Mar S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
